Aytu BioPharma reported a quarterly loss of $0.53 per share, missing the Zacks Consensus Estimate for a $0.31 loss by $0.22 per share. That also compares unfavorably with earnings of $0.20 per share a year ago, signaling a meaningful deterioration in profitability. The report is likely to pressure the stock, though the article contains no revenue or guidance details.
Aytu BioPharma reported a quarterly loss of $0.53 per share, missing the Zacks Consensus Estimate for a $0.31 loss by $0.22 per share. That also compares unfavorably with earnings of $0.20 per share a year ago, signaling a meaningful deterioration in profitability. The report is likely to pressure the stock, though the article contains no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
